Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: Mol Pharm. 2019 Jun 27;16(8):3534–3543. doi: 10.1021/acs.molpharmaceut.9b00369

Figure 1.

Figure 1

SDS-PAGE analysis of TfRMAb-N292G-EPO under reducing (lane 2) and non-reducing (lane 3) conditions (A). High-affinity binding of the WT and N292G mutant TfRMAb-EPO fusion proteins to TfR (B) and EPOR (C).